Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· December 12, 2025

Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer

View original at finance.yahoo.com

Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Breast cancer is the 2nd most diagnosed cancer worldwide after lung cancer
80% confidence
With an additional year of follow-up, EMBER-3 results strengthen the case for imlunestrant-based regimens in ER+, HER2– metastatic breast cancer
80% confidence
Eli Lilly medicines help tens of millions of people globally
80% confidence
Updated EMBER-3 data demonstrate continued clinically meaningful benefit for patients receiving monotherapy and those receiving the combination with abemaciclib, reinforcing Inluriyo's role in the treatment setting
80% confidence
Eli Lilly is encouraged by the potential of an all-oral combination with imlunestrant and abemaciclib
80% confidence
The median progression-free survival of 11 months is among the longest seen in ER+, HER2– metastatic breast cancer population
80% confidence